Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study-Reference-Cited by-同舟云学术

Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study

Published:2018-07 Issue:10142 Volume:392 Page:134-144
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Landewé Robert,Sieper Joachim,Mease Philip,Inman Robert D,Lambert Robert G,Deodhar Atul,Marzo-Ortega Helena,Magrey Marina,Kiltz Uta,Wang Xin,Li Mei,Zhong Sheng,Mostafa Nael M,Lertratanakul Apinya,Pangan Aileen L,Anderson Jaclyn K

Publisher

Elsevier BV

Subject

General Medicine

Reference30 articles.

1. Axial spondyloarthritis: is there a treatment of choice?;Poddubnyy;Ther Adv Musculoskelet Dis,2013

2. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1);Sieper;Ann Rheum Dis,2013

3. Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis;Sieper;Ann Rheum Dis,2012

4. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis;Baji;Eur J Health Econ,2014

5. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study;Arends;Arthritis Res Ther,2011

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment strategies for Spondyloarthritis: Implementation of precision medicine – Or “one size fits all” concept?;Autoimmunity Reviews;2024-09

2. The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations;Expert Opinion on Biological Therapy;2024-08-02

3. Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies;Expert Review of Clinical Immunology;2024-07-29

4. Axial spondyloarthritis—current aspects;Exploration of Musculoskeletal Diseases;2024-07-24

5. Dose Tapering and Discontinuation of Biologic DMARDs in Axial Spondyloarthritis: A Narrative Review (2023 SPARTAN Annual Meeting Proceedings);Current Rheumatology Reports;2024-02-09